Ranibizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ranibizumab: Toward Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
The evidence pack does not document Ranibizumab’s original approved indication, so this report focuses on the predicted new use. The TxGNN model predicts Ranibizumab may be effective for Severe Nonproliferative Diabetic Retinopathy (Severe NPDR), supported by 6 clinical trials (including two completed Phase 3 trials) and 19 publications. Notably, the evidence itself indicates this is less a novel “repurposing” hypothesis than confirmation of an already mature, near-standard-of-care use of anti-VEGF therapy in diabetic retinopathy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (data gap) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Ranibizumab is not available in this evidence pack (flagged as a High-severity data gap). However, the repurposing rationale supplied with the prediction states that Ranibizumab is an anti-VEGF-A monoclonal antibody fragment, and that VEGF is a central driver of the vascular leakage and neovascularisation underlying diabetic retinopathy (DR) pathophysiology.
Because of this direct mechanistic fit, the evidence pack itself notes that anti-VEGF therapy with ranibizumab is already approved elsewhere for DR — meaning this candidate is not a typical speculative “new use,” but rather a well-established application supported by mature clinical evidence. The two completed Phase 3 trials in the evidence base (NCT02634333, n=399; NCT00444600, n=691) reinforce that the drug-disease link is grounded in confirmatory rather than exploratory data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02634333 | Phase 3 | Completed | 399 | Intravitreal anti-VEGF treatment for prevention of vision-threatening complications in high-risk diabetic retinopathy eyes |
| NCT00444600 | Phase 3 | Completed | 691 | DRCR.net protocol comparing ranibizumab vs. triamcinolone, with/without laser, for diabetic macular edema in DR |
| NCT04503551 | Phase 3 | Active, not recruiting | 174 | Port Delivery System with ranibizumab vs. comparator for efficacy/safety/PK in DR without center-involved DME |
| NCT03452657 | Phase 3 | Unknown | 118 | Intravitreal ranibizumab vs. sham injection for prevention of high-risk DR progression |
| NCT02834663 | Phase 4 | Completed | 25 | Single-center pilot on ranibizumab’s effect on microaneurysm turnover and nonperfused retinal area in NPDR with DME |
| NCT05222633 | N/A | Unknown | 1000 | Real-world observational registry of anti-VEGF therapy across AMD, PDR, macular edema and CNV (low disease-specificity to Severe NPDR) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40048178 | 2025 | RCT | JAMA Ophthalmology | Pavilion trial: Port Delivery System with ranibizumab vs. monitoring reduces risk of progression to vision-threatening complications in NPDR |
| 32606578 | 2020 | RCT | Clinical Ophthalmology | Predictors of early DR regression with ranibizumab in the RIDE/RISE trials |
| 35417296 | 2022 | RCT | Ophthalmic Surgery, Lasers & Imaging Retina | Post hoc analysis of DR progression in untreated fellow eyes from RIDE/RISE |
| 28448655 | 2017 | RCT (secondary analysis) | JAMA Ophthalmology | 2-year DR change comparing aflibercept, bevacizumab, and ranibizumab |
| 39673354 | 2024 | Systematic Review / Meta-analysis | Health Technology Assessment | Anti-VEGF drugs vs. laser photocoagulation for diabetic retinopathy |
| 40347224 | 2025 | Systematic Review | Health Technology Assessment | Anti-VEGF vs. laser photocoagulation for DR, including economic analysis |
| 33966556 | 2021 | Review | Expert Opinion on Biological Therapy | Overview of ranibizumab for the treatment of diabetic retinopathy |
| 31669065 | 2019 | Review | Journal of Diabetes and its Complications | Advances in the treatment of diabetic retinopathy, VEGF-A as key target |
| 36774994 | 2023 | Meta-analysis / Cohort | Ophthalmology Retina | Baseline DR severity and time to DME resolution with ranibizumab |
| 30973596 | 2019 | Cohort | JAMA Ophthalmology | Retinal nonperfusion characteristics in severe NPDR vs. PDR on ultra-widefield angiography |
Denmark Market Information
Ranibizumab is not currently marketed in Denmark — no marketing authorisations (national Laegemiddelstyrelsen or centralised EMA) are on file in this evidence pack.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug interaction data are not available in this evidence pack.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Evidence Level L1 is supported by two completed Phase 3 RCTs and additional ongoing/completed trials, and the mechanism (anti-VEGF-A blockade of a core DR pathogenic pathway) is well aligned with the predicted indication — consistent with the evidence pack’s own observation that ranibizumab is already an established anti-VEGF therapy for DR elsewhere. However, Ranibizumab currently has no marketing authorisation in Denmark, and drug-level safety/label data are missing.
To proceed, the following is needed:
- TFDA/SmPC-equivalent product label with warnings and contraindications (Blocking gap, DG001)
- Documented mechanism of action (DG002)
- Original (historical) indication documentation for this evidence pack
- Assessment of the regulatory pathway for Danish market authorisation, given current “not marketed” status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.